Getting Healthy with Acquisitions, New Products, and Favorable Court Rulings - Research Report on AstraZeneca, Herbalife,

Getting Healthy with Acquisitions, New Products, and Favorable Court Rulings -
Research Report on AstraZeneca, Herbalife, CardioNet, Cyberonics, and NuVasive

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, June 17, 2013

NEW YORK, June 17, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting
AstraZeneca plc (ADR) (NYSE: AZN), Herbalife Ltd. (NYSE: HLF), CardioNet Inc.
(NASDAQ: BEAT), Cyberonics, Inc. (NASDAQ: CYBX) and NuVasive, Inc. (NASDAQ:
NUVA). Today's readers may access these reports free of charge - including
full price targets, industry analysis and analyst ratings - via the links
below.

AstraZeneca plc (ADR) Research Report

On June 10, 2013, AstraZeneca plc (AstraZeneca) announced that it has entered
into a definitive agreement to acquire Pearl Therapeutics, (Pearl) a privately
held company that develops inhaled small-molecule therapeutics for respiratory
disease. According to AstraZeneca, this acquisition will enable it to have
access to a potential new treatment for chronic obstructive pulmonary disease
(COPD), currently in late-stage development, and inhaler and formulation
technology that provides a platform for future combination products.
AstraZeneca will acquire all of Pearl's shares for initial consideration of
$560.0 million payable on completion. Deferred consideration of up to $450.0
million will be payable if specified development and regulatory milestones in
respect of any triple combination therapies and selected future products that
AstraZeneca develops using Pearl's technology platform are achieved.
Sales-related payments of up to $140.0 million are payable if pre-agreed
cumulative sales thresholds are exceeded, resulting in a total potential
acquisition cost of up to $1.2 billion. The transaction is expected to close
in Q3 2013, subject to customary regulatory approvals. The Full Research
Report on AstraZeneca plc (ADR) - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/02c7_AZN]

--

Herbalife Ltd. Research Report

On June 11, 2013, Herbalife Ltd. (Herbalife) released the results of a study
conducted to determine the penetration of Herbalife distributors and end users
in the United States. According to the Nielsen research, conducted online
during April and May 2013, 3.3% of the general population reported that they
had purchased Herbalife products within the past three months, indicating that
the Company's products currently has 7.9 million customers when projected to
the total U.S. adult population. The consumers include the Company's
distributor network, which totaled approximately 550,000 in the U.S. as of the
end of Q1 2013. Michael O. Johnson, Herbalife's Chairman and Chief Executive
Officer, commented, "We believe the results of this study substantiate our
belief that many of those who attack our model lack a clear understanding of
the direct selling industry, and Herbalife in particular." The Full Research
Report on Herbalife Ltd. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/9c8f_HLF]

--

CardioNet Inc. Research Report

On June 10, 2013, CardioNet Inc. (CardioNet) announced that the Company has
entered into a three-year National Provider Agreement with UnitedHealthcare
Insurance Company, covering all of its monitoring modalities, including Mobile
Cardiac Outpatient Telemetry (MCOT). Joseph Capper, President and Chief
Executive Officer of CardioNet, said, "By providing access to United's more
than 70 million members, this agreement dramatically expands the available
market for all of our life-saving technologies." The agreement came into an
effect on July 1, 2013 and applies to all the Company's affiliated entities,
including managed Medicare and managed Medicaid plans. The Full Research
Report on CardioNet Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/d815_BEAT]

--

Cyberonics,Inc. Research Report

On June 5, 2013, Cyberonics Inc. (Cyberonics) announced its financial results
for Q4 FY 2013 and full-year FY 2013 (period ended April 26, 2013). For Q4 FY
2013, the Company's net sales increased 18.6% YoY to $68.3 million. For
full-year FY 2013, the Company's net sales increased 16.4% YoY to $254.3
million. Dan Moore, Cyberonics' President and Chief Executive Officer, said,
"The results demonstrate the underlying strength of our worldwide epilepsy
business, as well as the ongoing opportunity within the underserved population
of people suffering from epilepsy." He added, "In fiscal 2014, we expect to
submit both our AspireSR and ProGuardian™ products for regulatory approval in
Europe, as well as advance the Relay generator through product development."4
Full Research Report on Cyberonics, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.wsreports.com/r/full_research_report/a55c_CYBX]

--

NuVasive,Inc. Research Report

On June 12, 2013, NuVasive, Inc. (NuVasive) announced that it received a
ruling from the U.S. District Court regarding its ongoing royalty rates for
Phase I of its patent litigation with Medtronic. As part of the verdict in the
Phase I of the litigation, royalty rates were determined by the jury as
follows: 10.0% on certain of NuVasive's CoRoent XL implants and 3.0% on
certain MaXcess retractors and related products. Before the appeal in Phase I
could move forward, the District Court was required to determine the ongoing
royalty rates applicable to these products during the period of time following
the verdict. Medtronic previously requested ongoing royalty rates of 36.0% on
the applicable NuVasive CoRoent XL implants and 11.0% on the applicable
MaXcess retractors and related products. In the ruling received on June 12,
2013, the District Court ordered royalty rates of 13.75% on the applicable
CoRoent XL implants and 8.25% on the applicable MaXcess retractors. The Full
Research Report on NuVasive, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/c367_NUVA]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquires, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)